For research use only. Not for therapeutic Use.
4-Phenylbutyric acid-d11 (CAS: 358730-86-6), a premium pharmaceutical research compound designed for advanced metabolic and biochemical studies. As a deuterated analog of 4-Phenylbutyric acid, it offers enhanced stability and improved pharmacokinetic properties. 4-Phenylbutyric acid-d11 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel metabolic therapies. Trusted by leading laboratories, 4-Phenylbutyric acid-d11 is your go-to solution for cutting-edge metabolic research. Unlock new possibilities in metabolic studies with 4-Phenylbutyric acid-d11, where innovation meets reliability.
Catalog Number | S000251 |
CAS Number | 358730-86-6 |
Molecular Formula | C10HD11O2 |
Purity | ≥95% |
Target | Epigenetics |
IUPAC Name | 2,2,3,3,4,4-hexadeuterio-4-(2,3,4,5,6-pentadeuteriophenyl)butanoic acid |
InChI | InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)/i1D,2D,3D,4D2,5D,6D,7D2,8D2 |
InChIKey | OBKXEAXTFZPCHS-VRWITDQQSA-N |
SMILES | [2H]C1=C(C(=C(C(=C1[2H])[2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C(=O)O)[2H])[2H] |
Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Chang TH, et al. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res. 2002 Apr;8(4):1206-12 [3]. Frouco G, et, al. Sodium phenylbutyrate abrogates African swine fever virus replication by disrupting the virus-induced hypoacetylation status of histone H3K9/K14. Virus Res. 2017 Oct 15;242:24-29. [4]. Park HJ, et al. 4-Phenylbutyric acid protects against lipopolysaccharide-induced bone loss by modulating autophagy in osteoclasts. Biochem Pharmacol. 2018 May;151:9-17. |